TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
Early Access of TMC114 in Combination With Low-dose Ritonavir (TMC/r)) and Other Antiretrovirals (ARVs) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to no Treatment Options.
Sponsor: Tibotec Pharmaceuticals, Ireland
This observational or N/A phase trial investigates HIV Infections and is currently ongoing. Tibotec Pharmaceuticals, Ireland leads this study, which shows 11 recorded versions since 2026 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Approved For Marketing
-
Oct 2025 — Jan 2026 [monthly]
Approved For Marketing
-
Sep 2025 — Oct 2025 [monthly]
Approved For Marketing
-
Sep 2024 — Sep 2025 [monthly]
Approved For Marketing
-
Jul 2024 — Sep 2024 [monthly]
Approved For Marketing
▶ Show 6 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Approved For Marketing
-
Jun 2018 — Jan 2021 [monthly]
Approved For Marketing
-
Apr 2018 — Jun 2018 [monthly]
Approved For Marketing
Phase: NA → None
-
Jul 2017 — Apr 2018 [monthly]
Approved For Marketing NA
Phase: PHASE3 → NA
-
Feb 2017 — Jul 2017 [monthly]
Approved For Marketing PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Approved For Marketing PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Tibotec Pharmaceuticals, Ireland
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aachen, Germany , Aalborg, Denmark , Aarau, Switzerland , Aarhus, Denmark , Akron, United States , Albany, United States , Albuquerque, United States , Alicante, Spain , Alkmaar, Netherlands and 377 more locations